IX Biopharma(42C.SI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

42C.SI IX Biopharma

Not Yet Opened 11-05 17:06:00 SGT Delay

0.0230

+0.0000

0.00%

High0.0230	Low0.0230	Vol0.00
Open0.0230	D1 Closing0.0230	Amplitude0.00%
Mkt Cap20.32M	Tradable Cap11.06M	Total Shares883.34M
T/O0.00	T/O Rate0.00%	Tradable Shares480.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"42C.SI","market":"SI","secType":"STK","nameCN":"IX Biopharma","latestPrice":0.023,"timestamp":1730797560043,"preClose":0.023,"halted":0,"volume":0,"delay":15,"nameEN":"IX Biopharma","floatShares":480699976,"shares":883336340,"eps":-0.0141,"marketStatus":"Not Yet Opened","change":0,"latestTime":"11-05 17:06:00 SGT Delay","open":0.023,"high":0.023,"low":0.023,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0141,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1730853000000},"marketStatusCode":0,"adr":0,"exchange":"SGX","adjPreClose":0.023,"openAndCloseTimeList":[[1730766600000,1730779200000],[1730782800000,1730798160000]],"volumeRatio":0,"lotSize":100,"tradeCurrency":"SGD"},"requestUrl":"/m/hq/s/42C.SI","defaultTab":"news","newsList":[{"id":"2475553601","title":"IX Biopharma Appoints Scientific Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2475553601","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475553601?lang=en_us&edition=fundamental","pubTime":"2024-10-15 13:15","pubTimestamp":1728969311,"startTime":"0","endTime":"0","summary":"IX Biopharma  added Brian Kennedy as scientific advisor to its scientific advisory board, according to a Monday filing with the Singapore Exchange.Kennedy is the director of the Healthy Longevity Translational Research Program at the National University of Singapore.He will help the healthcare company develop its healthspan supplements through its supplements subsidiary, Entity Health, the filing stated.Price : S$18502.69, Change: S$+160, Percent Change: +0.87%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":0},{"id":"2472439136","title":"iX Biopharma Schedules Extraordinary General Meeting for Scheme Extensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2472439136","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472439136?lang=en_us&edition=fundamental","pubTime":"2024-10-01 10:52","pubTimestamp":1727751160,"startTime":"0","endTime":"0","summary":"iX Biopharma  will hold an extraordinary general meeting on Oct. 17 at 11:00 a.m. at its Singapore headquarters, according to a Tuesday filing on the Singapore Exchange.The meeting will address three resolutions: extending the iX Employee Share Option Scheme  and the iX Performance Share Plan  for an additional 10 years, until June 16, 2035, and allowing Eddy Lee Yip Hang, a controlling shareholder, to participate in the extended iX PSP.Both schemes will limit total shares issued to 15% of the company's total issued shares, excluding treasury shares and subsidiary holdings.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6506","42C.SI"],"gpt_icon":1},{"id":"2468801165","title":"iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401","url":"https://stock-news.laohu8.com/highlight/detail?id=2468801165","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468801165?lang=en_us&edition=fundamental","pubTime":"2024-09-17 10:41","pubTimestamp":1726540898,"startTime":"0","endTime":"0","summary":"iX Biopharma  has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome  and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["42C.SI","BK6079","BK6506"],"gpt_icon":0},{"id":"2467890591","title":"IX Biopharma Ltd. Press Release - Business and Drug Development Updates - Wafermine and Ixb 401","url":"https://stock-news.laohu8.com/highlight/detail?id=2467890591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467890591?lang=en_us&edition=fundamental","pubTime":"2024-09-16 17:37","pubTimestamp":1726479479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nTUE3NDQ0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","42C.SI","BK6079"],"gpt_icon":0},{"id":"2462693413","title":"iX Biopharma's Net Attributable Loss Widens in Fiscal H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2462693413","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462693413?lang=en_us&edition=fundamental","pubTime":"2024-08-26 12:46","pubTimestamp":1724647565,"startTime":"0","endTime":"0","summary":"iX Biopharma's  net loss attributable to equity holders widened to SG$3.5 million in the six months ended June 30, from SG$2.3 million in the year-ago period, a filing with the Singapore Exchange said on Friday.Loss per share came in at SG$0.0045, from SG$0.0030 per share in the comparable period.Revenue for the fiscal second half was down 3% year over year to SG$3.3 million from SG$3.4 million, mainly due to lower revenue from the medicinal cannabis and other pharma segments.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":1},{"id":"2459913104","title":"iX Biopharma's CBD Wafer Shows Potential in Improving Symptoms for Kidney Failure Patients; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459913104","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459913104?lang=en_us&edition=fundamental","pubTime":"2024-08-13 11:15","pubTimestamp":1723518951,"startTime":"0","endTime":"0","summary":"iX Biopharma (SGX:42C) disclosed the results from its SEISMIC-CBD study on a new cannabidiol (CBD) sublingual wafer, according to a Monday filing with the Singapore Exchange.The study evaluated the wa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":1},{"id":"2453841557","title":"IX Biopharma Issues 115 Million Rights Shares, 57.5 Million Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2453841557","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453841557?lang=en_us&edition=fundamental","pubTime":"2024-07-22 11:25","pubTimestamp":1721618710,"startTime":"0","endTime":"0","summary":"IX Biopharma  allotted and issued 115,018,984 rights shares and 57,509,492 warrants under the rights cum warrants issue, according to a filing with the Singapore Exchange on Friday.Following the allotment and issuance, the number of issued and paid-up shares in the company's capital will increase from 768.3 million to 883.3 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":0},{"id":"2452744703","title":"Singapore Shares Track Global Losses to End Week in Red; GRP Shares Climb 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452744703","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452744703?lang=en_us&edition=fundamental","pubTime":"2024-07-19 18:03","pubTimestamp":1721383399,"startTime":"0","endTime":"0","summary":"Singapore's stock market retreated on Friday, tracking overnight losses in the US and European markets, led by a sell-off on tech stocks.The Straits Times Index , a key benchmark for the Singapore Exchange, ranged between 3,437.85 and 3,457.31 throughout the day. It ended the session at 3,447.56, down 23.60 points or 0.68% compared to Thursday's close.In company news, shares of GRP  were up over 3% as it entered into an agreement with Lian Ee Hydraulics for the proposed disposal of assets, inventory, goodwill, and customer contracts of its wholly-owned subsidiary, GRP Pte, for SG$680,000.Lum Chang  closed 3% higher on Friday as it repurchased 51,900 shares in the open market for SG$15,326 or SG$0.29421 apiece.Meanwhile, IX Biopharma  disclosed the results of its rights cum warrants issue, which closed on July 15. The company received valid acceptances and excess applications for 115 million rights shares with warrants, representing 68.1% of the available 169 million shares.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["L19.SI","BLU.SI","BK6045","BK6079","BK6520","42C.SI","STI.SI","BK6506","BK6517","BK6057"],"gpt_icon":1},{"id":"2452659494","title":"IX Biopharma Raises SG$3.3 Million from Rights Cum Warrants Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2452659494","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452659494?lang=en_us&edition=fundamental","pubTime":"2024-07-19 11:03","pubTimestamp":1721358227,"startTime":"0","endTime":"0","summary":"IX Biopharma  disclosed the results of its rights cum warrants issue, which closed on July 15, according to a Thursday filing on the Singapore Exchange.The company received valid acceptances and excess applications for 115 million rights shares with warrants, representing 68.1% of the available 169 million shares.The rights issue, which offered 115 million shares, included 88.3 million from valid acceptances and 26.7 million from excess applications. The company will allocate 80.7 million shares to satisfy excess applications.The net proceeds from the issue, amounting to approximately SG$3.3 million, will be allocated as follows: 57% for product development and marketing, including iXB401 sublingual semaglutide wafers, and 43% for general working capital.Rights shares and warrants are expected to be issued on July 19, with listing on Catalist anticipated on July 23 for the shares and July 24 for the warrants.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6506","42C.SI"],"gpt_icon":0},{"id":"2450802880","title":"iX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2450802880","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450802880?lang=en_us&edition=fundamental","pubTime":"2024-07-10 10:40","pubTimestamp":1720579222,"startTime":"0","endTime":"0","summary":"iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.The study evaluated the impact o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6506","42C.SI"],"gpt_icon":0},{"id":"2444416038","title":"Ix Biopharma Cuts Conversion Price of 9% Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2444416038","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444416038?lang=en_us&edition=fundamental","pubTime":"2024-06-19 11:33","pubTimestamp":1718767991,"startTime":"0","endTime":"0","summary":"Ix Biopharma  adjusted the conversion price of its SG$2 million 9% convertible bonds following its recent rights cum warrants issue, according to a Tuesday filing with the Singapore bourse. The conversion price of the bonds will be reduced from SG$0.1337 to SG$0.1200 per share, while the minimum conversion price will decrease from SG$0.0819 to SG$0.0700, effective June 25, when the shares trade ex-rights.The adjustment follows the companys rights issue of up to 172.3 million new shares at SG$0.03 per share and 86.2 million free detachable warrants at an exercise price of SG$0.06 per share. The bondholder, Lau Ho Ming Peter, has not yet exercised his conversion rights. Based on the adjusted minimum conversion price, iX Biopharma could issue up to 28.57 million new shares.Shares of Ix Biopharma plunged nearly 8.6% in recent trade. Price : S$0.03, Change: S$, Percent Change: -8.57%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["42C.SI","BK6506","BK6079"],"gpt_icon":0},{"id":"2442363969","title":"Singapore Shares Fall As Federal Interest Rate Cut Hopes Dim; China Mining Up 29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442363969","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2442363969?lang=en_us&edition=fundamental","pubTime":"2024-06-11 17:42","pubTimestamp":1718098973,"startTime":"0","endTime":"0","summary":"Singapore's Straits Times Index was down on Tuesday closing after strong US jobs figures dimmed hopes of an early Federal interest rate cut.During the day, the benchmark Singapore Strait Times Index ranged between 3,303.24 and 3,332.60, ending 0.39% or 12.87 points lower at 3,309.21.In economic news, the Business Sentiment Index in Singapore rose further in the third quarter as the wholesale sector saw slight improvements in optimism levels, according to a press release by the Singapore Commercial Credit Bureau .In company news, shares of China Mining  surged nearly 29% after the company appointed Guo Wenjun as the companys new chief executive officer, effective June 28.In company news, shares of Eurosports Global  shares surged over 10% after it bought back 20,000 shares in the open market on Monday for SG$2,905 or SG$0.143 apiece.Shares of iX Biopharma  were up nearly 3% after the company revealed that it is looking to raise nearly SG$5 million through a renounceable non-underwritten","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["5G1.SI","42C.SI"],"gpt_icon":0},{"id":"2442552813","title":"iX Biopharma to Raise Up to SG$5 Million from Rights Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2442552813","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2442552813?lang=en_us&edition=fundamental","pubTime":"2024-06-11 15:56","pubTimestamp":1718092599,"startTime":"0","endTime":"0","summary":"iX Biopharma  is looking to raise nearly SG$5 million through a renounceable non-underwritten rights share and warrant issue of up to around 172.3 million new ordinary shares and 86.2 million warrants, respectively, a Tuesday filing on the Singapore bourse said. The rights shares, which will be issued at SG$0.03 apiece on the basis of 11 rights shares for every 50 existing shares held by qualifying shareholders, will be exercisable at SG$0.06 apiece. The free detachable and transferable warrants will be issued on the basis of one warrant for every two rights shares. One warrant will carry the right to subscribe for one new ordinary share in the pharmaceutical and nutraceutical companys share capital at SG$0.06 apiece. Shares of the company were down nearly 3% in recent trade.Price : S$0.03, Change: S$, Percent Change: -2.86%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6506","42C.SI"],"gpt_icon":1}],"profile":{"websiteUrl":"https://www.ixbiopharma.com/","stockEarnings":[{"period":"1week","weight":-0.08},{"period":"1month","weight":-0.1154},{"period":"3month","weight":-0.08},{"period":"6month","weight":-0.425},{"period":"1year","weight":-0.4524},{"period":"ytd","weight":-0.4889}],"compareEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0.1151},{"period":"6month","weight":0.1235},{"period":"1year","weight":0.1809},{"period":"ytd","weight":0.1549}],"compareStock":{"symbol":"ES3.SI","name":"STI ETF"},"description":"IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.027006},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.011688},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.070233},{"month":4,"riseRate":0.555556,"avgChangeRate":0.083753},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.03685},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.027088},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014632},{"month":8,"riseRate":0.1,"avgChangeRate":-0.105321},{"month":9,"riseRate":0.5,"avgChangeRate":-0.010732},{"month":10,"riseRate":0.4,"avgChangeRate":-0.010195},{"month":11,"riseRate":0.3,"avgChangeRate":-0.01671},{"month":12,"riseRate":0.666667,"avgChangeRate":0.040149}],"exchange":"SGX","name":"IX Biopharma","nameEN":"IX Biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IX Biopharma(42C.SI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IX Biopharma(42C.SI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IX Biopharma,42C.SI,IX Biopharma股票,IX Biopharma股票老虎,IX Biopharma股票老虎国际,IX Biopharma行情,IX Biopharma股票行情,IX Biopharma股价,IX Biopharma股市,IX Biopharma股票价格,IX Biopharma股票交易,IX Biopharma股票购买,IX Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IX Biopharma(42C.SI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IX Biopharma(42C.SI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction